Compare ALTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | CLLS |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | France |
| Employees | 490 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 384.3M |
| IPO Year | 2021 | 2014 |
| Metric | ALTI | CLLS |
|---|---|---|
| Price | $3.79 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 143.6K | 37.9K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $254,956,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $10.71 | $0.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.96 | $1.33 |
| 52 Week High | $5.45 | $5.48 |
| Indicator | ALTI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 63.19 |
| Support Level | $3.73 | $3.93 |
| Resistance Level | $3.95 | $4.46 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 75.33 | 71.16 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.